FOCL
EDAP TMS S.A. American Depositary Shares
FOCL trails on the overall score without a compensating advantage in the available component scores.
OSCR
Oscar Health, Inc.
OSCR has the edge over FOCL overall, supported by stronger fundamentals.
FOCL Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Under pressure | |
| Healthy |
FOCL's balance sheet is currently healthy, but its revenue, profitability and cash flow are under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
FOCL PE Valuation
FOCL has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
FOCL Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Decline | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect FOCL's losses to shrink, with revenue declining.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over FOCL on the outlook, with more favorable revenue expectations.
FOCL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.98 | -$0.39 |
| Q2 2024 | -$0.58 | -$0.07 |
| Q1 2024 | -$0.54 | -$0.23 |
| Q4 2023 | -$0.63 | -$0.55 |
| Q3 2023 | -$0.63 | -673% |
| Q2 2023 | -$0.51 | -738% |
| Q1 2023 | -$0.31 | -3200% |
| Q4 2022 | -$0.08 | -500% |
FOCL lost $0.98 per share over the past year, a bigger loss than the year before.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over FOCL on earnings quality, reporting a profit while its opponent remains loss making.
FOCL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $9.8M | -39% |
| Q2 2026 | $13.2M | -27% |
| Q1 2026 | $17.8M | +25% |
| Q4 2025 | $21.9M | +0.9% |
| Q2 2025 | $18.2M | +7% |
| Q1 2025 | $14.3M | -12% |
| Q4 2024 | $21.7M | +2.8% |
| Q2 2024 | $17M | +9.4% |
FOCL's revenue is shrinking: $10M last quarter, down 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -79% | -44 points |
| Q2 2026 | -61% | -25 points |
| Q1 2026 | -41% | +2.9 points |
| Q4 2025 | -28% | -9.1 points |
| Q3 2025 | -35% | N/A |
| Q2 2025 | -36% | +3 points |
| Q1 2025 | -44% | -12 points |
| Q4 2024 | -18% | -0.6 points |
FOCL's operating margin was −79% last quarter, down 44 points from the same quarter a year ago, near the bottom of its range since 2015.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over FOCL on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over FOCL on profitability, with a higher operating margin.
FOCL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$4M | +$891.5K |
| Q2 2026 | -$3.7M | +$2.4M |
| Q1 2026 | -$3M | +$3.7M |
| Q4 2025 | -$4.1M | -$3.4M |
| Q3 2025 | -$4.9M | +$1.6M |
| Q2 2025 | -$6.1M | +$1.4M |
| Q1 2025 | -$6.6M | -$1.4M |
| Q4 2024 | -$642.7K | +$1.4M |
FOCL has burned cash in most quarters: −$15M over the past year, against −$18M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over FOCL on cash generation, producing positive trailing cash flow while its opponent burns cash.
FOCL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +14% | +5.1M shares |
| 1 year | +14% | +5.2M shares |
| 3 years | +15% | +5.6M shares |
| 5 years | +32% | +10.4M shares |
| Available history | +58% | +15.6M shares |
FOCL has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
FOCL Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2022 | -12.2x | Net Cash |
| Q2 2022 | -13.3x | Net Cash |
| Q1 2022 | -85.7x | Net Cash |
| Q4 2021 | -148.8x | Net Cash |
| Q3 2021 | -49.2x | Net Cash |
| Q2 2021 | -27.7x | Net Cash |
FOCL has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
FOCL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.0 | Neutral |
| Stochastic | 4.9 | Oversold |
FOCL's weekly RSI is 38 (neutral) and its Stochastic is 5 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
FOCL PE vs Healthcare Sector
| Metric | FOCL | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
FOCL has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
FOCL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.03 | 15% below |
| 20 week MA | $4.62 | 26% below |
| 50 week MA | $4.20 | 19% below |
| 100 week MA | $3.12 | 9.3% above |
| 200 week MA | $4.98 | 32% below |
FOCL's trend is mixed: it's above one of its five weekly moving averages, and 32% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over FOCL on trend strength, trading above more of its moving averages.
FOCL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.40 | $5.08 | +15% |
| 2021 | $5.08 | $5.65 | +11% |
| 2022 | $5.65 | $10.5 | +86% |
| 2023 | $10.5 | $5.28 | -50% |
| 2024 | $5.28 | $2.17 | -59% |
| 2025 | $2.17 | $3.40 | +57% |
| 2026 YTD | $3.40 | $3.41 | +0.3% |
FOCL has finished higher in four of the last six years, two of them by more than 50%. It's roughly flat so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over FOCL on returns for 2026, with the stronger performance.